#USA #Class Action #San Francisco #Regeneron Pharmaceuticals #Hagens Berman

Regeneron Pharmaceuticals Under Legal Fire

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing a securities class action lawsuit following disappointing results from its Phase 3 clinical trial aimed at treating melanoma patients. This news became public on April 29, 2026, when the company disclosed that the trial failed to meet its key endpoint, a revelation that led to a substantial decline in its stock price and wiped approximately $11 billion off its market cap.

Hagens Berman Sobol Shapiro LLP, a prominent shareholder rights law firm, has initiated a class action urging investors who have suffered significant losses to join the lawsuit. The firm is currently investigating Regeneron’s legal obligations regarding its disclosures, particularly around statements that the firm made leading up to the trial’s outcome.

Context of the Lawsuit

The lawsuit involves claims that Regeneron provided misleading statements about the clinical trial's potential success. The trial, concerning the treatment of melanoma through a combination therapy featuring Fianlimab and Libtayo, was initially touted as a game-changer, possibly a “blockbuster” drug. However, during the course of the trial, concerns about its effectiveness began mounting, with management persistently assuring investors that results would be favorable until the very end.

Critics allege that Regeneron was aware that preliminary data indicated the combination treatment was not significantly outperforming existing options. The company allegedly failed to inform investors of critical changes to the study protocols that could impact the interpreted success of the trial results.

Key Developments

The timeline of events leading to the lawsuit spans crucial announcements and changes in the trial protocol:

• - April 29, 2026: Regeneron revealed adjustments to its trial protocol, admitting that the primary survival analysis would now include all enrolled patients after a minimum follow-up of six months. This overhaul raised eyebrows among analysts, suggesting serious underlying issues with the trial’s design.
• - May 12, 2026: Regeneron acknowledged that changing the trial protocol was a response to unexpectedly slow rates of disease progression among participants. The firm seemed initially optimistic but later conceded that a revision was necessary.
• - May 15, 2026: The hammer fell when Regeneron announced that the trial did not achieve statistical significance for its primary endpoint, contradicting the previous management statements that projected a positive outcome based on trial performance.

Investors' Action

Consequently, Hagens Berman is calling on affected investors to submit their claims. The firm is looking for individuals who purchased or acquired Regeneron's common stock between August 1, 2025, and May 15, 2026. The deadline for investors to act as lead plaintiffs is set for September 14, 2026, and Hagens Berman is actively encouraging individuals with relevant information to contact its attorneys for investigation.

Conclusion

As the Regeneron case unfolds, it poses significant implications for both the firm and its investors. Corporate accountability is at the heart of this lawsuit, illustrating the delicate balance of investor relations and the responsibilities of pharmaceutical companies surrounding clinical trials. Hagens Berman’s exploration of potential misconduct can set a precedent that might influence how companies report clinical trial data and manage investor expectations in the future. For Regeneron investors, the outcome of this class action holds crucial importance as it may redefine their investment landscape amidst the backdrop of corporate accountability in healthcare.